| Keywords: |
immunohistochemistry; signal transduction; treatment response; unclassified drug; gene mutation; overall survival; cytotoxic agent; erlotinib; cancer combination chemotherapy; drug efficacy; drug safety; patient selection; note; cancer patient; temozolomide; antineoplastic agent; polymerase chain reaction; cell death; dna damage; gene targeting; gastrointestinal stromal tumor; imatinib; melanoma; quality of life; ovary cancer; pharmacodynamics; breast cancer; aromatase inhibitor; lung cancer; dasatinib; chronic myeloid leukemia; drug design; brca1 protein; brca2 protein; heterozygote; cetuximab; fluorescence in situ hybridization; double stranded dna; drug mechanism; colon cancer; vandetanib; tamoxifen; physician; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; excision repair; maximum tolerated dose; trastuzumab; nilotinib; lapatinib; fulvestrant; olaparib; thyroid medullary carcinoma; molecular therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); 8 fluoro 3,4 dihydro 2 [4 (methylaminomethyl)phenyl]pyrrolo[3,4,5 e,f][2]benzazepin 6(5h) one; mk 4827; triple negative breast cancer; veliparib; crizotinib; vemurafenib; cep 9722; pf 01367338; pf 0137338
|
